Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy

Antimicrob Agents Chemother. 2008 Apr;52(4):1542-4. doi: 10.1128/AAC.01301-07. Epub 2008 Feb 4.

Abstract

We evaluated the safety and efficacy of a twice daily regimen containing 400 mg of indinavir and 100 mg of ritonavir in 32 human immunodeficiency virus (HIV)-infected women during pregnancy. The median indinavir trough concentration was 208 ng/ml during the third trimester. At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / transmission
  • HIV Infections / virology
  • HIV-1 / drug effects
  • Humans
  • Indinavir / administration & dosage
  • Indinavir / therapeutic use*
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / virology
  • Pregnancy Outcome
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / administration & dosage
  • Ritonavir / therapeutic use*
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Indinavir
  • Ritonavir